DrugPatentWatch Database Preview
Indivior Inc Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for INDIVIOR INC, and what generic alternatives to INDIVIOR INC drugs are available?
INDIVIOR INC has six approved drugs.
There are twenty-one US patents protecting INDIVIOR INC drugs.
There are two hundred and twenty-eight patent family members on INDIVIOR INC drugs in thirty-five countries and one supplementary protection certificate in one country.
Summary for Indivior Inc
| International Patents: | 228 |
| US Patents: | 21 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 6 |
| Patent Litigation for Indivior Inc: | See patent lawsuits for Indivior Inc |
Drugs and US Patents for Indivior Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indivior Inc | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-001 | Jul 27, 2018 | RX | Yes | No | 10,010,612 | Start Trial | Y | Start Trial | |||
| Indivior Inc | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-004 | Aug 10, 2012 | AB | RX | Yes | Yes | 9,931,305 | Start Trial | Y | Start Trial | ||
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-002 | Nov 30, 2017 | RX | Yes | Yes | 9,272,044 | Start Trial | Start Trial | ||||
| Indivior Inc | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-002 | Jul 27, 2018 | RX | Yes | Yes | 9,597,402 | Start Trial | Y | Start Trial | |||
| Indivior Inc | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-002 | Jul 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INDIVIOR INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Sublingual Film | 2 mg/0.5 mg and 8 mg/2 mg | ➤ Subscribe | 2012-10-15 |
| ➤ Subscribe | Sulingual Film | 12 mg/3 mg | ➤ Subscribe | 2014-03-26 |
| ➤ Subscribe | Sublingual Film | 4 mg/1 mg | ➤ Subscribe | 2013-05-14 |
International Patents for Indivior Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2017200626 | Start Trial |
| Israel | 254417 | Start Trial |
| Australia | 2002362772 | Start Trial |
| Norway | 20056060 | Start Trial |
| China | 100356908 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Indivior Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0196132 | 94C0008 | Belgium | Start Trial | PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
